Description
+ Include: 8 videos + 1 pdf, size: 25.1 GB
+ Target Audience: pediatricians, infectious disease specialists, obstetricians/gynecologists
+ Sample video: contact me for sample video
+ Information:
CMV 2021 2nd Congress on Congenital CMV 21 – 22 OCTOBER 2021 Rome, Italy
Scientific Goal
The most prevalent congenital infection and the first cause of non genetic hearing loss continues to be largely ignored or misunderstood outside expert circles. We invite all care providers to attend this meeting to meet the experts and improve their practice for a better outcome.
Congress Topics
- The risks in pregnancy are well defined
- Screening and diagnostic tools are efficient, and quality control is effective
- Primary prevention is part of preconceptional medicine
- Vaccine technology has been revolutionized by the COVID pandemic
- Diagnosis is as reliable prenatally and postnatally
- Secondary and tertiary prevention are efficient and should be widely implemented
- Postnatal care has been simplified and rationalized
- Sensorineural hearing loss is not a fatality
- Are there any late complications other than hearing impairment is asymptomatic children?
- Sensorineural hearing loss is not a fatality
- Hearing rehabilitation in cCMV children with unilateral hearing loss
- Is there an association between CMV infections and ADD/Autism/Schizophrenia?
- Brain imaging for children with cCMV – Ultrasound or MRI?
- Universal screening for cCMV
- Early diagnosis of cCMV using Chorionic villus sampling
- Vestibular problems in symptomatic and asymptomatic cCMV
- What can we offer to asymptomatic children with late onset hearing loss?
The 2nd Congress on Congenital Cytomegalovirus 2021 was aimed at a diverse group of healthcare professionals involved in the care and research of congenital cytomegalovirus (CMV). The target audience included:
- Pediatricians
- Infectious Disease Specialists
- Obstetricians/Gynecologists
- Nurses and Nurse Practitioners
- Physician Assistants
- Researchers and Scientists in the field of CMV and related areas
This event provided a platform for these professionals to discuss the latest research, clinical practices, and advancements in the understanding and management of congenital CMV.
+ Topics:
1 Welcome and SESSION 1 – Asymptomatic children with cCMV.mp4
2 Debate 1 UNIVERSAL NEONATAL SCREENING.mp4
3 SESSION 2 – Infection during pregnancy.mp4
4 DEBATE Vaccines – adults or toddlers.mp4
5 SESSION 4 Fetal infection.mp4
6 DEBATE Invasive Diagnosis the earlier the better.mp4
7 SESSION 5 – Hearing loss, vestibular disorders and rehabilitation in children with cCMV and Closing.mp4
8 Congenital CMV infection how to implement the diagnostics and the clinical follow up.mp4
Program.pdf
* Detail:
21 October
22 October
09:00-12:00 SESSION 4 Fetal infection Moderators: Karl Oliver Kagan, Germany
09:00-09:20 International registry on the use of valaciclovir for secondary prevention Valentine Faure-Bardon, France
09:20-09:40 Hyperimmune globulins, how and how much Karl Oliver Kagan, Germany
09:40-10:00 Screening in pregnancy, what can you get for your money? Valérie Seror, France
10:00-10:20 Screening in pregnancy, why not then? Anna Gonce, Spain
10:20-10:45 Discussion
10:45-11:15 COFFEE BREAK
11:15-12:00 DEBATE: Invasive Diagnosis the earlier the better Yves Ville, France Vs. Schlomo Lipitz, Israel
12:00-12:20 Do we need to perform brain MRI in every infant with Ccmv? Efi Bilavsky, Israel
12:20-13:30 LUNCH AND POSTER VIEWING
13:30-16:15 SESSION 5 – Hearing loss, vestibular disorders and rehabilitation in children with cCMV Moderators: Ina Foulon, Belgium
13:00-13:20 Hearing loss in children with cCMV – from the broad spectrum to the individual Blake Papsin, Canada
13:20-13:40 How do we diagnose and treat vestibular problems in children with CCMV? Natacha Teissier, France
13:40-14:00 Hearing and vestibular rehabilitation in children with unilateral hearing loss Blake Papsin, Canada
14:00-14:15 Discussion
14:15-14:25 (ID 10) – The CONCERT Study: Treatment of Infants with Congenital Cytomegalovirus Infection and Isolated Hearing Loss, Detected Through Newborn Hearing Screening P.K. Chung, the Netherlands
14:25-14:35 (ID 4) – The effect of (val)ganciclovir on hearing in congenital cytomegalovirus: a systematic review. Elise De Cuyper, Belgium
14:35-14:45 (ID 40) – Immunogenicity Findings From a Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an mRNA- Based Vaccine Against Cytomegalovirus Infection Lori Panther, United States
14:45-14:55 (ID 43) – Universal newborn screening for congenital CMV infection: a prospective multicenter clinical trial Liliana Gabrielli, Italy
14:55-15:05 (ID 49) – Prognostic value of mild cerebral features in infected fetuses treated in utero after maternal infection in the first trimester N BOURGON, France
15:05-15:30 COFFEE BREAK
15:30-15:40 (ID 18) – Unmet needs in maternal diagnosis and treatment for congenital CMV in France: data from the French “congenital CMV declaration platform” of the National Reference Center for Herpesviruses Elodie Ribot, France
15:40-15:50 (ID 22) Cortical maturation assessed by magnetic resonance imaging in unaffected/mildly affected fetuses with cytomegalovirus infection. Ameth Hawkins-Villarreal, Spain
15:50-16:00 (ID 23) Performance of targeted congenital cytomegalovirus screening in newborns failing universal hearing screening: a multicenter study Jacques Fourgeaud, France
16:00-16:15 Discussion
16:15-16:45 Anti-CMV Vaccines. Any lesson learned from the Covid pandemic? Shilpe Sharma, Belgium
16:45-17:00 CLOSING REMARKS Yves Ville, Efraim Bilavsky
Reviews
There are no reviews yet.